Barron’s bullish on Onyx; Invitrogen names integration team leader; Genta can resume trial

> Impressed by the market potential of Nexavar, an article in the influential financial publication Barron's points to the positive in Onyx Pharmaceuticals. Report

> Invitrogen has tapped Mark Smedley, its head of global operations, to head up the integration team in charge of handling the Applied Biosystems buyout. Report

> Genetic test maker Sequenom says it will sell 5.5 million shares to the public. Sequenom release

> MacAndrews & Forbes has agreed to supply up to $8 million in financing to Siga Technologies. Siga release

> Novartis has announced details of two new long-term outcome studies in its landmark Aspire Higher clinical trial program which has expanded to involve more than 35,000 patients in 14 trials. The newly-launched studies will evaluate the organ protection potential of the first-in-class direct renin inhibitor Rasilez, known as Tekturna in the US. Novartis report

> Apparently, it's not just a few activist Congressional reps who want doctors to fess up to payments from pharmaceutical companies. A new poll found that Americans want to know whether their physicians are getting gifts or payments from drugmakers. Report

> Seems like a match made in marketing heaven. Merck has been pushing its Gardasil vaccine--designed to prevent cervical cancer and genital warts by fending off the human papilloma virus--via ads in movie theaters showing Sex and the City. Gardasil report

> Pfizer said it isn't buying a majority stake in Ranbaxy Laboratories. Report

> Globalization and generic drugs: There's a collection of news today that illustrates a couple of trends that have taken firm hold in the drug-sales world, two trends that are inextricably linked. Report

> Some big stocks were down to multiyear lows last week--including Pfizer and Merck, a deveopment that runs counter to pharma's traditional position as a defensive stronghold. Pharma report

And Finally...Scientists have now isolated the "selfish" gene. Release

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.